17 results
8-K
EX-99.1
OGEN
Oragenics Inc
18 Mar 24
Oragenics Appoints James Kelly MD, Chief Medical Officer to Lead Phase II Clinical Trials for Treating Concussion
7:38am
to enhance brain exposure and metabolism in animals. “Our Phase I human study has shown ONP-002 to be well tolerated in humans. Our mission now
8-K
EX-99.1
OGEN
Oragenics Inc
2 Nov 23
Oragenics Issues Update to Shareholders
7:00am
as they unfold.
Thank you for your continued support of Oragenics. I encourage you to vote at the annual meeting and support our mission to impact even more
DEFA14A
OGEN
Oragenics Inc
2 Nov 23
Additional proxy soliciting materials
7:00am
. I encourage you to vote at the annual meeting and support our mission to impact even more lives and improve human health in meaningful ways. Proxy
8-K
EX-99.1
OGEN
Oragenics Inc
5 Oct 23
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
6:30am
company with a focus on life-enhancing medical solutions. Odyssey’s corporate mission is to create, acquire and develop distinct assets, intellectual
8-K
EX-99.1
u7dlfb5qsa5itahm6
5 Jun 23
Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM
4:30pm
424B5
sisat66rlndiy63aqqpa
28 Dec 20
Prospectus supplement for primary offering
4:59pm
424B5
dh9qof 1t
20 Nov 20
Prospectus supplement for primary offering
4:52pm
424B5
suteghk
19 Nov 20
Prospectus supplement for primary offering
4:22pm
8-K
EX-99.1
dj1dz vnbl8o90zq68uu
28 Sep 20
Oragenics Provides an Update on Funding for its SARS-CoV-2 Vaccine
7:45am
8-K
EX-99.1
c3l6oi5vmrwnbj
14 Dec 11
Oragenics Announces Fourth Amendment to Unsecured Revolving Line of Credit to Provide $500,000 of Additional Funding
12:00am
8-K
EX-99.1
9mem5t350t
15 Jan 09
Regulation FD Disclosure
12:00am
8-K
mxopqp4tp7 n3vvcf
8 Feb 05
Other Events
12:00am
- Prev
- 1
- Next